Loading…
3.5% urea-linked gelatin is as effective as 6% HES 200/0.5 for volume management in cardiac surgery patients
To compare the efficacy of volume expansion with 3.5% gelatin and 6% hydroxyethyl starch 200/0.5 in patients undergoing cardiac surgery. The second objective was to compare the two colloids in terms of blood losses and allogeneic blood transfusion exposure rate. In this open-label controlled study,...
Saved in:
| Published in: | Canadian journal of anesthesia 2004-03, Vol.51 (3), p.236-241 |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c376t-c33659ce26b539541352df9f732a72bbad9d044b1dd46fb7a2c71436cdf1fe463 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c376t-c33659ce26b539541352df9f732a72bbad9d044b1dd46fb7a2c71436cdf1fe463 |
| container_end_page | 241 |
| container_issue | 3 |
| container_start_page | 236 |
| container_title | Canadian journal of anesthesia |
| container_volume | 51 |
| creator | VAN DER LINDEN, Philippe J DE HERT, Stefan G DAPER, Anne TRENCHANT, Anne SCHMARTZ, Denis DEFRANCE, Pierre KIMBIMBI, Pierre |
| description | To compare the efficacy of volume expansion with 3.5% gelatin and 6% hydroxyethyl starch 200/0.5 in patients undergoing cardiac surgery. The second objective was to compare the two colloids in terms of blood losses and allogeneic blood transfusion exposure rate.
In this open-label controlled study, patients were randomly allocated to receive either 3.5% urea-linked gelatin (GEL group: n = 55) or 6% hydroxyethyl starch 200/0.5/5.1 (HES group: n = 55) for per- (including priming of the bypass machine) and postoperative volume management with a maximum dosage of 30 +/- 3 mL.kg(-1).day(-1). Volume replacement was guided according to routine per- and postoperative care based on cardiac index, mixed venous oxygen saturation, and diuresis. If additional colloid was required, 4.5% albumin had to be given. The study period comprised per- and postoperative investigations up to 18 hr after surgery.
All hemodynamic variables were comparable in both groups. Total study drug was 25.8 +/- 4.8 mL.kg(-1) in the GEL group and 24.5 +/- 6.0 mL.kg(-1) in the HES group. There was no difference in the number of patients receiving albumin solution or in the amount of albumin administered. Total blood loss was higher in the HES than in the GEL group (11.0 +/- 7.8 mL.kg(-1) vs 8.7 +/- 4.0 mL.kg(-1); P < 0.05) resulting in a higher need for allogeneic blood transfusion (HES: nine patients received 12 units, GEL two patients received 3 units; P = 0.026).
In the conditions of the present study, HES was not associated with a better plasma expansion effect than GEL. HES could result in a higher need for allogeneic blood transfusion. |
| doi_str_mv | 10.1007/BF03019102 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71722108</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2418502041</sourcerecordid><originalsourceid>FETCH-LOGICAL-c376t-c33659ce26b539541352df9f732a72bbad9d044b1dd46fb7a2c71436cdf1fe463</originalsourceid><addsrcrecordid>eNpdkU1rHDEMhk1JaTbbXvoDiglsD4HZyN_jYxvyUQj00BZ6Gzy2vEw6H1t7ZiH_vg5ZSMlFQujRK_GKkI8MtgzAXH69AQHMMuBvyIpJq6vaGnVCVlALXmkGv0_JWc4PAFBrVb8jp0wBAwlqRXqxVRu6JHRV341_MNAd9m7uRtpl6jLFGNHP3QGfCr2hd9c_KAe4hK2icUr0MPXLgHRwo9vhgONMy6h3KXTO07ykHaZHui-CpZXfk7fR9Rk_HPOa_Lq5_nl1V91_v_129eW-8sLouUShlfXIdauEVZIJxUO00QjuDG9bF2wAKVsWgtSxNY57w6TQPkQWUWqxJp-fdfdp-rtgnpuhyx773o04LbkxzHDOijtrcv4KfJiWNJbbmrpmwrDayAJdPEM-TTknjM0-dYNLjw2D5ukBzcsDCvzpqLi0A4YX9Oh4ATZHwGXv-pjc6Lv8H6fB2rL7H4cViZE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>881371874</pqid></control><display><type>article</type><title>3.5% urea-linked gelatin is as effective as 6% HES 200/0.5 for volume management in cardiac surgery patients</title><source>Springer Link</source><creator>VAN DER LINDEN, Philippe J ; DE HERT, Stefan G ; DAPER, Anne ; TRENCHANT, Anne ; SCHMARTZ, Denis ; DEFRANCE, Pierre ; KIMBIMBI, Pierre</creator><creatorcontrib>VAN DER LINDEN, Philippe J ; DE HERT, Stefan G ; DAPER, Anne ; TRENCHANT, Anne ; SCHMARTZ, Denis ; DEFRANCE, Pierre ; KIMBIMBI, Pierre</creatorcontrib><description>To compare the efficacy of volume expansion with 3.5% gelatin and 6% hydroxyethyl starch 200/0.5 in patients undergoing cardiac surgery. The second objective was to compare the two colloids in terms of blood losses and allogeneic blood transfusion exposure rate.
In this open-label controlled study, patients were randomly allocated to receive either 3.5% urea-linked gelatin (GEL group: n = 55) or 6% hydroxyethyl starch 200/0.5/5.1 (HES group: n = 55) for per- (including priming of the bypass machine) and postoperative volume management with a maximum dosage of 30 +/- 3 mL.kg(-1).day(-1). Volume replacement was guided according to routine per- and postoperative care based on cardiac index, mixed venous oxygen saturation, and diuresis. If additional colloid was required, 4.5% albumin had to be given. The study period comprised per- and postoperative investigations up to 18 hr after surgery.
All hemodynamic variables were comparable in both groups. Total study drug was 25.8 +/- 4.8 mL.kg(-1) in the GEL group and 24.5 +/- 6.0 mL.kg(-1) in the HES group. There was no difference in the number of patients receiving albumin solution or in the amount of albumin administered. Total blood loss was higher in the HES than in the GEL group (11.0 +/- 7.8 mL.kg(-1) vs 8.7 +/- 4.0 mL.kg(-1); P < 0.05) resulting in a higher need for allogeneic blood transfusion (HES: nine patients received 12 units, GEL two patients received 3 units; P = 0.026).
In the conditions of the present study, HES was not associated with a better plasma expansion effect than GEL. HES could result in a higher need for allogeneic blood transfusion.</description><identifier>ISSN: 0832-610X</identifier><identifier>EISSN: 1496-8975</identifier><identifier>DOI: 10.1007/BF03019102</identifier><identifier>PMID: 15010405</identifier><identifier>CODEN: CJOAEP</identifier><language>eng</language><publisher>Toronto, ON: Canadian Anesthesiologists' Society</publisher><subject>Adult ; Aged ; Anesthesia ; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy ; Biological and medical sciences ; Blood Transfusion ; Blood transfusions ; Cardiac Surgical Procedures ; Colloids ; Female ; Gelatin - administration & dosage ; Hemostasis ; Humans ; Hydroxyethyl Starch Derivatives - administration & dosage ; Male ; Medical sciences ; Middle Aged ; Plasma Volume ; Postoperative period ; Surgery</subject><ispartof>Canadian journal of anesthesia, 2004-03, Vol.51 (3), p.236-241</ispartof><rights>2004 INIST-CNRS</rights><rights>Canadian Anesthesiologists 2004.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c376t-c33659ce26b539541352df9f732a72bbad9d044b1dd46fb7a2c71436cdf1fe463</citedby><cites>FETCH-LOGICAL-c376t-c33659ce26b539541352df9f732a72bbad9d044b1dd46fb7a2c71436cdf1fe463</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,786,790,27957,27958</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15609981$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15010405$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>VAN DER LINDEN, Philippe J</creatorcontrib><creatorcontrib>DE HERT, Stefan G</creatorcontrib><creatorcontrib>DAPER, Anne</creatorcontrib><creatorcontrib>TRENCHANT, Anne</creatorcontrib><creatorcontrib>SCHMARTZ, Denis</creatorcontrib><creatorcontrib>DEFRANCE, Pierre</creatorcontrib><creatorcontrib>KIMBIMBI, Pierre</creatorcontrib><title>3.5% urea-linked gelatin is as effective as 6% HES 200/0.5 for volume management in cardiac surgery patients</title><title>Canadian journal of anesthesia</title><addtitle>Can J Anaesth</addtitle><description>To compare the efficacy of volume expansion with 3.5% gelatin and 6% hydroxyethyl starch 200/0.5 in patients undergoing cardiac surgery. The second objective was to compare the two colloids in terms of blood losses and allogeneic blood transfusion exposure rate.
In this open-label controlled study, patients were randomly allocated to receive either 3.5% urea-linked gelatin (GEL group: n = 55) or 6% hydroxyethyl starch 200/0.5/5.1 (HES group: n = 55) for per- (including priming of the bypass machine) and postoperative volume management with a maximum dosage of 30 +/- 3 mL.kg(-1).day(-1). Volume replacement was guided according to routine per- and postoperative care based on cardiac index, mixed venous oxygen saturation, and diuresis. If additional colloid was required, 4.5% albumin had to be given. The study period comprised per- and postoperative investigations up to 18 hr after surgery.
All hemodynamic variables were comparable in both groups. Total study drug was 25.8 +/- 4.8 mL.kg(-1) in the GEL group and 24.5 +/- 6.0 mL.kg(-1) in the HES group. There was no difference in the number of patients receiving albumin solution or in the amount of albumin administered. Total blood loss was higher in the HES than in the GEL group (11.0 +/- 7.8 mL.kg(-1) vs 8.7 +/- 4.0 mL.kg(-1); P < 0.05) resulting in a higher need for allogeneic blood transfusion (HES: nine patients received 12 units, GEL two patients received 3 units; P = 0.026).
In the conditions of the present study, HES was not associated with a better plasma expansion effect than GEL. HES could result in a higher need for allogeneic blood transfusion.</description><subject>Adult</subject><subject>Aged</subject><subject>Anesthesia</subject><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</subject><subject>Biological and medical sciences</subject><subject>Blood Transfusion</subject><subject>Blood transfusions</subject><subject>Cardiac Surgical Procedures</subject><subject>Colloids</subject><subject>Female</subject><subject>Gelatin - administration & dosage</subject><subject>Hemostasis</subject><subject>Humans</subject><subject>Hydroxyethyl Starch Derivatives - administration & dosage</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Plasma Volume</subject><subject>Postoperative period</subject><subject>Surgery</subject><issn>0832-610X</issn><issn>1496-8975</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><recordid>eNpdkU1rHDEMhk1JaTbbXvoDiglsD4HZyN_jYxvyUQj00BZ6Gzy2vEw6H1t7ZiH_vg5ZSMlFQujRK_GKkI8MtgzAXH69AQHMMuBvyIpJq6vaGnVCVlALXmkGv0_JWc4PAFBrVb8jp0wBAwlqRXqxVRu6JHRV341_MNAd9m7uRtpl6jLFGNHP3QGfCr2hd9c_KAe4hK2icUr0MPXLgHRwo9vhgONMy6h3KXTO07ykHaZHui-CpZXfk7fR9Rk_HPOa_Lq5_nl1V91_v_129eW-8sLouUShlfXIdauEVZIJxUO00QjuDG9bF2wAKVsWgtSxNY57w6TQPkQWUWqxJp-fdfdp-rtgnpuhyx773o04LbkxzHDOijtrcv4KfJiWNJbbmrpmwrDayAJdPEM-TTknjM0-dYNLjw2D5ukBzcsDCvzpqLi0A4YX9Oh4ATZHwGXv-pjc6Lv8H6fB2rL7H4cViZE</recordid><startdate>20040301</startdate><enddate>20040301</enddate><creator>VAN DER LINDEN, Philippe J</creator><creator>DE HERT, Stefan G</creator><creator>DAPER, Anne</creator><creator>TRENCHANT, Anne</creator><creator>SCHMARTZ, Denis</creator><creator>DEFRANCE, Pierre</creator><creator>KIMBIMBI, Pierre</creator><general>Canadian Anesthesiologists' Society</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8FQ</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20040301</creationdate><title>3.5% urea-linked gelatin is as effective as 6% HES 200/0.5 for volume management in cardiac surgery patients</title><author>VAN DER LINDEN, Philippe J ; DE HERT, Stefan G ; DAPER, Anne ; TRENCHANT, Anne ; SCHMARTZ, Denis ; DEFRANCE, Pierre ; KIMBIMBI, Pierre</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c376t-c33659ce26b539541352df9f732a72bbad9d044b1dd46fb7a2c71436cdf1fe463</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Anesthesia</topic><topic>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</topic><topic>Biological and medical sciences</topic><topic>Blood Transfusion</topic><topic>Blood transfusions</topic><topic>Cardiac Surgical Procedures</topic><topic>Colloids</topic><topic>Female</topic><topic>Gelatin - administration & dosage</topic><topic>Hemostasis</topic><topic>Humans</topic><topic>Hydroxyethyl Starch Derivatives - administration & dosage</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Plasma Volume</topic><topic>Postoperative period</topic><topic>Surgery</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>VAN DER LINDEN, Philippe J</creatorcontrib><creatorcontrib>DE HERT, Stefan G</creatorcontrib><creatorcontrib>DAPER, Anne</creatorcontrib><creatorcontrib>TRENCHANT, Anne</creatorcontrib><creatorcontrib>SCHMARTZ, Denis</creatorcontrib><creatorcontrib>DEFRANCE, Pierre</creatorcontrib><creatorcontrib>KIMBIMBI, Pierre</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database (ProQuest)</collection><collection>Health & Medical Collection (Proquest)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Canadian Business & Current Affairs Database</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Canadian journal of anesthesia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>VAN DER LINDEN, Philippe J</au><au>DE HERT, Stefan G</au><au>DAPER, Anne</au><au>TRENCHANT, Anne</au><au>SCHMARTZ, Denis</au><au>DEFRANCE, Pierre</au><au>KIMBIMBI, Pierre</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>3.5% urea-linked gelatin is as effective as 6% HES 200/0.5 for volume management in cardiac surgery patients</atitle><jtitle>Canadian journal of anesthesia</jtitle><addtitle>Can J Anaesth</addtitle><date>2004-03-01</date><risdate>2004</risdate><volume>51</volume><issue>3</issue><spage>236</spage><epage>241</epage><pages>236-241</pages><issn>0832-610X</issn><eissn>1496-8975</eissn><coden>CJOAEP</coden><notes>ObjectType-Article-2</notes><notes>SourceType-Scholarly Journals-1</notes><notes>ObjectType-Feature-1</notes><notes>ObjectType-News-3</notes><notes>content type line 23</notes><abstract>To compare the efficacy of volume expansion with 3.5% gelatin and 6% hydroxyethyl starch 200/0.5 in patients undergoing cardiac surgery. The second objective was to compare the two colloids in terms of blood losses and allogeneic blood transfusion exposure rate.
In this open-label controlled study, patients were randomly allocated to receive either 3.5% urea-linked gelatin (GEL group: n = 55) or 6% hydroxyethyl starch 200/0.5/5.1 (HES group: n = 55) for per- (including priming of the bypass machine) and postoperative volume management with a maximum dosage of 30 +/- 3 mL.kg(-1).day(-1). Volume replacement was guided according to routine per- and postoperative care based on cardiac index, mixed venous oxygen saturation, and diuresis. If additional colloid was required, 4.5% albumin had to be given. The study period comprised per- and postoperative investigations up to 18 hr after surgery.
All hemodynamic variables were comparable in both groups. Total study drug was 25.8 +/- 4.8 mL.kg(-1) in the GEL group and 24.5 +/- 6.0 mL.kg(-1) in the HES group. There was no difference in the number of patients receiving albumin solution or in the amount of albumin administered. Total blood loss was higher in the HES than in the GEL group (11.0 +/- 7.8 mL.kg(-1) vs 8.7 +/- 4.0 mL.kg(-1); P < 0.05) resulting in a higher need for allogeneic blood transfusion (HES: nine patients received 12 units, GEL two patients received 3 units; P = 0.026).
In the conditions of the present study, HES was not associated with a better plasma expansion effect than GEL. HES could result in a higher need for allogeneic blood transfusion.</abstract><cop>Toronto, ON</cop><pub>Canadian Anesthesiologists' Society</pub><pmid>15010405</pmid><doi>10.1007/BF03019102</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0832-610X |
| ispartof | Canadian journal of anesthesia, 2004-03, Vol.51 (3), p.236-241 |
| issn | 0832-610X 1496-8975 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71722108 |
| source | Springer Link |
| subjects | Adult Aged Anesthesia Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy Biological and medical sciences Blood Transfusion Blood transfusions Cardiac Surgical Procedures Colloids Female Gelatin - administration & dosage Hemostasis Humans Hydroxyethyl Starch Derivatives - administration & dosage Male Medical sciences Middle Aged Plasma Volume Postoperative period Surgery |
| title | 3.5% urea-linked gelatin is as effective as 6% HES 200/0.5 for volume management in cardiac surgery patients |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-22T03%3A30%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=3.5%25%20urea-linked%20gelatin%20is%20as%20effective%20as%206%25%20HES%20200/0.5%20for%20volume%20management%20in%20cardiac%20surgery%20patients&rft.jtitle=Canadian%20journal%20of%20anesthesia&rft.au=VAN%20DER%20LINDEN,%20Philippe%20J&rft.date=2004-03-01&rft.volume=51&rft.issue=3&rft.spage=236&rft.epage=241&rft.pages=236-241&rft.issn=0832-610X&rft.eissn=1496-8975&rft.coden=CJOAEP&rft_id=info:doi/10.1007/BF03019102&rft_dat=%3Cproquest_cross%3E2418502041%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c376t-c33659ce26b539541352df9f732a72bbad9d044b1dd46fb7a2c71436cdf1fe463%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=881371874&rft_id=info:pmid/15010405&rfr_iscdi=true |